Headlines about Oncomed Pharmaceuticals (NASDAQ:OMED) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oncomed Pharmaceuticals earned a daily sentiment score of 0.05 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.7706135342747 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
NASDAQ:OMED traded down $0.12 on Thursday, reaching $2.29. The company’s stock had a trading volume of 110,700 shares, compared to its average volume of 132,698. Oncomed Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $5.56. The stock has a market cap of $88.55 million, a price-to-earnings ratio of -2.20 and a beta of 1.71.
Oncomed Pharmaceuticals (NASDAQ:OMED) last posted its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.13. The business had revenue of $6.87 million during the quarter, compared to analyst estimates of $7.49 million. equities analysts expect that Oncomed Pharmaceuticals will post -0.64 earnings per share for the current year.
A number of research firms have issued reports on OMED. Zacks Investment Research cut Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 21st. ValuEngine raised Oncomed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Oncomed Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $4.30.
About Oncomed Pharmaceuticals
OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway.
Featured Story: Hedge Funds
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.